Graham Baker - Smith Nephew Chief Financial Officer, Executive Director

<div class='logoBackup' style='background:#0D8ECF;color: white;font-size:3em;;'>SNN</div>
SNN -- USA Stock  

USD 49.10  0.19  0.39%

  Director
Mr. Graham Baker is Chief Financial Officer, Executive Director of the Company. He joined the Board as Chief Financial Officer in March 2017. He is based in London, UK. Career and experience Graham holds an MA degree in Economics from Cambridge University and qualified as a Chartered Accountant and Chartered Tax Adviser with Arthur Andersen. In 1995, he joined AstraZeneca PLC where he worked for 20 years, holding multiple senior roles, including Vice President Finance Chief Financial Officer, North America, Vice President, Global Financial Services and Vice President, Finance, International 20132015 with responsibility for all emerging markets. Most recently, Graham was Chief Financial Officer of generic pharmaceuticals company Alvogen. Skills and competencies Graham has deep sector knowledge and has had extensive exposure to established and emerging markets which is extremely relevant to his role at Smith Nephew. He has a strong track record of delivering operational excellence and has relevant experience across major finance roles and geographic markets, leading large teams responsible for significant budgets.
Age: 49  Director Since 2017      
44 19 2347 7100  http://www.smith-nephew.com

Management Efficiency

The company has Return on Asset of 7.62 % which means that on every $100 spent on asset it made $7.62 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 14.55 % implying that it generated $14.55 on every 100 dollars invested.
The company has 2.18 B in debt with debt to equity (D/E) ratio of 44.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Smith Nephew SNATS has Current Ratio of 1.96 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robin FreestoneSmith Nephew Plc O
2019
Samuel ScottAbbott Laboratories
2007
Warren ThalerAlign Technology
2004
Rajeev SuriStryker Corporation
N/A
Louise FrancesconiStryker Corporation
2006
Kristina JohnsonBoston Scientific Corporation
2011
Michael LeavittMedtronic plc
2011
James MullenInsulet Corporation
2017
Joseph ZakrzewskiInsulet Corporation
2008
Kevin DallasAlign Technology
2018
Charles LiamosInsulet Corporation
2014
Ian BarlowSmith Nephew Plc O
2017
Gail BoudreauxZimmer Biomet Holdings
2012
Daniel StarksAbbott Laboratories
2017
Martha MarshEdwards Lifesciences Corporatio
2015
Andrea SaiaAlign Technology
2013
Ellen ZaneBoston Scientific Corporation
2016
David RouxBoston Scientific Corporation
2015
Kieran GallahueEdwards Lifesciences Corporatio
2015
Jessica HopfieldInsulet Corporation
2016
William OsbornAbbott Laboratories
2013

Entity Summary

Smith Nephew plc develops, manufactures, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in USA and is traded on BATS Exchange. It employs 16000 people.Smith Nephew SNATS (SNN) is traded on BATS Exchange in USA and employs 16,000 people.

Smith Nephew SNATS Leadership Team

Namal Nawana, Chief Executive Officer, Executive Director
Michael Friedman, Non-Executive Independent Director
Diogo MoreiraRato, President - Europe and Canada
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Independent Director
Matthew Stober, President - Global Operations
Marc Owen, Non-Executive Independent Director
Rodrigo Bianchi, Interim President - Asia Pacific
Brian Larcombe, Senior Independent Non-Executive Director
Elga Lohler, Chief Human Resource Officer
Gunthorp Oie, IR Contact Officer
Roland Diggelmann, Non-Executive Independent Director
Helen Maye, Chief Human Resources Officer
Vinita Bali, Non-Executive Independent Director
Simon Fraser, President - Advanced Wound Management
Massimiliano Colella, President Europe - Middle East and Africa
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee
Graham Baker, Chief Financial Officer, Executive Director
Cathy ORourke, Chief Legal and Compliance Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Cyrille Petit, Chief Corporate Development Officer
Julie Brown, CFO, Director and Member of Disclosures Committee
Glenn Warner, President - Advanced Wound Management
Robin Freestone, Senior Non-Executive Independent Director
Virginia Bottomley, Non-Executive Independent Director
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Independent Director
Mark Gladwell, President - Global Operations
Vasant Padmanabhan, President - Research & Development
Michael Frazzette, President - Advanced Surgical Devices
Joseph Papa, Non-Executive Independent Director
Ingeborg Oie, VP, Investor Relations
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Gordon Howe, President of Global Operations
John Campo, Chief Legal Officer
Brad Cannon, President - Sports Medicine & ENT
Ian Barlow, Non-Executive Independent Director
Catheryn ORourke, Chief Legal Officer

Stock Performance Indicators

Current Sentiment - SNN

Smith Nephew SNATS Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Smith Nephew SNATS. What is your outlook on investing in Smith Nephew SNATS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

SSM   
Sold over 100K shares of
3 days ago
Traded for 0.175
S32   
Purchased over 10K shares of
3 days ago
Traded for 2.5
BSL   
Purchased over 100 shares of
3 days ago
Traded for 15.49
MBI   
Purchased over 100 shares of
3 days ago
Traded for 9.2
MDLZ   
Purchased over 100 shares of
3 days ago
Traded for 54.19
Additionally take a look at World Market Map. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.